General Information

We are a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Our cancer-selective gene therapy platform is built on retroviral replicating vectors, or RRVs, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our gene therapy approach is designed to fight cancer through immunotherapeutic mechanisms of action without the autoimmune toxicities commonly experienced with other immunotherapies.

Employees: 61
Founded: 2007
Contact Information
Address 3030 Bunker Hill Street, Suite 230, San Diego, CA 92109, US
Phone Number (858) 412-8400
Web Address
View Prospectus: Tocagen
Financial Information
Market Cap $185.0mil
Revenues $0 mil (last 12 months)
Net Income $-33.4 mil (last 12 months)
IPO Profile
Symbol TOCA
Exchange NASDAQ
Shares (millions): 8.5
Price range $10.00 - $10.00
Est. $ Volume $85.0 mil
Manager / Joint Managers Leerink Partners/ Evercore ISI/ Stifel
CO-Managers -
Expected To Trade: 4/13/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change